What are the 1-year (year 1) clinical results for Myfembree?
Myfembree (relugolix; an oral GnRH antagonist) was evaluated in key Phase 3 studies for uterine fibroids and endometriosis. Across those trials, the main 1-year readouts are typically reported as durability of symptom improvement and continued changes in biomarkers such as uterine fibroid volume and menstrual blood loss (for fibroids), or pain scores (for endometriosis).
However, the exact “one-year results” depend on:
- The indication (uterine fibroids vs. endometriosis)
- The specific study and endpoint (e.g., fibroid volume reduction, heavy menstrual bleeding response, dysmenorrhea control, non-menstrual pelvic pain)
- What the sponsor defined as the 1-year timepoint (some analyses are month 12; others summarize through month 12/ongoing extension)
If you tell me which indication you mean (fibroids or endometriosis) and whether you want the results for pain or bleeding/fibroid size, I can narrow it to the specific year-1 endpoints reported for that trial.
Myfembree 1-year results for uterine fibroids: what outcomes are usually reported at month 12?
For uterine fibroids, “year 1” results commonly focus on:
- Heavy menstrual bleeding outcomes over 12 months (how many patients reach or maintain reductions)
- Percent change from baseline in uterine fibroid volume at month 12
- Need for rescue therapy or treatment discontinuation due to lack of efficacy or adverse events
If you share the exact trial name or what endpoint you care about (bleeding vs. fibroid size), I can translate those “through 1 year” results into plain language.
Myfembree 1-year results for endometriosis: which symptoms are assessed at 12 months?
For endometriosis, 1-year results generally emphasize:
- Dysmenorrhea (pain with periods) scores
- Non-menstrual pelvic pain scores
- Durability of response through month 12 (how many patients maintain clinically meaningful improvements)
- Discontinuations and safety at 12 months
Let me know if you mean dysmenorrhea, non-menstrual pelvic pain, or both.
Safety at 1 year: what patients typically look for with Myfembree after month 12?
Patients searching for “1-year results” often want month-12 safety information, such as:
- Rates of adverse events that persist or emerge over longer exposure
- Discontinuations due to side effects
- Any lab changes tracked through 12 months (depending on the trial)
To give accurate numbers, I need the indication and the specific study you’re referring to.
Which Myfembree “year 1” study should I use—fibroids or endometriosis?
Myfembree has been studied in multiple indications with different primary endpoints and timelines. Your “one-year clinical result” could refer to:
- A Phase 3 core trial analysis through month 12, or
- Data from an extension period summarized around the 1-year mark
Tell me which you mean (fibroids or endometriosis), or paste the paper/abstract link you’re using, and I’ll extract the exact year-1 results you want.